Trevi Therapeutics, which is developing an extended-release version of an opioid for new indications, raised $55 million by offering 5.5 million shares at $10, the downwardly revised price.
Trevi Therapeutics plans to list on the Nasdaq under the symbol TRVI. SVB Leerink, Stifel and BMO Capital Markets acted as lead managers on the deal.
